Jürgen Raths
Corporate Officer/Principal bij Executive Insight AG
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Neil Gibbons | M | - |
Executive Insight AG
| 23 jaar |
| Sandra Schoenes | M | - |
Executive Insight AG
| 15 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Mariola Söhngen | M | 63 | 15 jaar | |
| André L. Lamotte | M | 75 |
Arpida AG
 Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 jaar |
| Harry Welten | M | 59 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 8 jaar |
| Elmar Schnee | M | 65 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Michel Lucien Pettigrew | M | 71 |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Hans Fünfschilling | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Matthias Staehelin | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
| Dieter Gillessen | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 jaar |
| Bernhard Erni | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 jaar |
| Ivan Kompis | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | 12 jaar |
| Paul Verbraeken | M | - |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Zwitserland | 12 | 92.31% |
| Duitsland | 1 | 7.69% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jürgen Raths
- Persoonlijk netwerk
